Trigyn Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 2, 2026, 12:37 pm

Market Cap	160 Cr.
Current Price	51.9
Intrinsic Value	₹65.09
High / Low	102/50.0
Stock P/E	29.8
Book Value	247
Dividend Yield	0.00 %
ROCE	4.17 %
ROE	1.72 %
Face Value	10.0
PEG Ratio	-0.81

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Trigyn Technologies Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Trigyn Technologies Ltd	160 Cr.	51.9	102/50.0	29.8	247	0.00 %	4.17 %	1.72 %	10.0
Empower India Ltd	162 Cr.	1.39	2.74/1.06	40.6	2.64	0.00 %	1.78 %	1.73 %	1.00
Elnet Technologies Ltd	138 Cr.	346	421/312	6.99	414	0.55 %	15.4 %	11.9 %	10.0
Equippp Social Impact Technologies Ltd	184 Cr.	17.8	24.0/16.2	76.3	0.85	0.00 %	11.0 %	7.53 %	1.00
Xelpmoc Design and Tech Ltd	185 Cr.	125	165/78.5		52.1	0.00 %	13.0 %	13.4 %	10.0
Industry Average	17,201.42 Cr	439.88		101.91	120.81	0.73%	14.90%	21.00%	6.84

All Competitor Stocks of Trigyn Technologies Ltd

Quarterly Result

Metric	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	323.64	339.78	324.04	322.50	316.12	306.90	334.14	241.94	207.80	206.78	239.66	224.50	241.95
Expenses	306.53	317.16	316.07	304.80	299.96	323.41	316.78	232.47	203.44	207.41	234.15	226.82	239.76
Operating Profit	17.11	22.62	7.97	17.70	16.16	-16.51	17.36	9.47	4.36	-0.63	5.51	-2.32	2.19
OPM %	5.29%	6.66%	2.46%	5.49%	5.11%	-5.38%	5.20%	3.91%	2.10%	-0.30%	2.30%	-1.03%	0.91%
Other Income	1.27	2.47	2.23	3.21	3.10	2.42	3.26	4.00	3.18	4.40	3.96	4.19	4.05
Interest	0.53	0.54	0.47	0.42	0.38	0.33	0.53	0.33	0.27	0.29	1.88	0.54	0.63
Depreciation	1.67	1.70	1.78	1.67	1.58	1.55	2.07	1.27	1.47	1.03	1.24	0.78	0.86
Profit before tax	16.18	22.85	7.95	18.82	17.30	-15.97	18.02	11.87	5.80	2.45	6.35	0.55	4.75
Tax %	33.19%	32.87%	67.42%	35.76%	37.17%	37.88%	-5.33%	35.89%	93.79%	49.80%	59.69%	940.00%	-10.95%
Net Profit	10.81	15.34	2.59	12.09	10.86	-22.02	18.98	7.61	0.36	1.23	2.56	-4.61	5.27
EPS in Rs	3.51	4.98	0.84	3.93	3.53	-7.15	6.17	2.47	0.12	0.40	0.83	-1.50	1.71

Last Updated: December 28, 2025, 6:31 pm

Below is a detailed analysis of the quarterly data for Trigyn Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Sales, as of Sep 2025, the value is 241.95 Cr.. The value appears strong and on an upward trend. It has increased from 224.50 Cr. (Jun 2025) to 241.95 Cr., marking an increase of 17.45 Cr..
For Expenses, as of Sep 2025, the value is 239.76 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 226.82 Cr. (Jun 2025) to 239.76 Cr., marking an increase of 12.94 Cr..
For Operating Profit, as of Sep 2025, the value is 2.19 Cr.. The value appears strong and on an upward trend. It has increased from -2.32 Cr. (Jun 2025) to 2.19 Cr., marking an increase of 4.51 Cr..
For OPM %, as of Sep 2025, the value is 0.91%. The value appears strong and on an upward trend. It has increased from -1.03% (Jun 2025) to 0.91%, marking an increase of 1.94%.
For Other Income, as of Sep 2025, the value is 4.05 Cr.. The value appears to be declining and may need further review. It has decreased from 4.19 Cr. (Jun 2025) to 4.05 Cr., marking a decrease of 0.14 Cr..
For Interest, as of Sep 2025, the value is 0.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.54 Cr. (Jun 2025) to 0.63 Cr., marking an increase of 0.09 Cr..
For Depreciation, as of Sep 2025, the value is 0.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.78 Cr. (Jun 2025) to 0.86 Cr., marking an increase of 0.08 Cr..
For Profit before tax, as of Sep 2025, the value is 4.75 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Jun 2025) to 4.75 Cr., marking an increase of 4.20 Cr..
For Tax %, as of Sep 2025, the value is -10.95%. The value appears to be improving (decreasing) as expected. It has decreased from 940.00% (Jun 2025) to -10.95%, marking a decrease of 950.95%.
For Net Profit, as of Sep 2025, the value is 5.27 Cr.. The value appears strong and on an upward trend. It has increased from -4.61 Cr. (Jun 2025) to 5.27 Cr., marking an increase of 9.88 Cr..
For EPS in Rs, as of Sep 2025, the value is 1.71. The value appears strong and on an upward trend. It has increased from -1.50 (Jun 2025) to 1.71, marking an increase of 3.21.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 6:41 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	451	492	625	679	685	895	911	985	1,041	1,273	1,280	898	964
Expenses	407	456	563	612	623	810	833	893	975	1,212	1,245	880	959
Operating Profit	44	36	62	67	61	85	77	92	65	61	35	18	6
OPM %	10%	7%	10%	10%	9%	9%	8%	9%	6%	5%	3%	2%	1%
Other Income	56	5	2	1	1	-4	5	3	3	6	12	17	15
Interest	1	1	1	1	1	1	2	3	3	2	2	3	4
Depreciation	1	1	1	1	1	1	2	3	7	7	7	5	4
Profit before tax	98	40	62	66	60	78	78	89	59	58	38	26	13
Tax %	18%	39%	38%	41%	34%	38%	36%	30%	34%	40%	48%	56%
Net Profit	81	24	38	39	39	48	50	62	39	35	20	12	4
EPS in Rs	27.49	8.32	13.02	13.13	13.20	15.74	16.27	20.19	12.69	11.26	6.48	3.82	1.26
Dividend Payout %	0%	0%	0%	0%	0%	5%	2%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-70.37%	58.33%	2.63%	0.00%	23.08%	4.17%	24.00%	-37.10%	-10.26%	-42.86%	-40.00%
Change in YoY Net Profit Growth (%)	0.00%	128.70%	-55.70%	-2.63%	23.08%	-18.91%	19.83%	-61.10%	26.84%	-32.60%	2.86%

Trigyn Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	6%
5 Years:	0%
3 Years:	-5%
TTM:	-27%

Compounded Profit Growth
10 Years:	-5%
5 Years:	-23%
3 Years:	-30%
TTM:	-99%

Stock Price CAGR
10 Years:	9%
5 Years:	8%
3 Years:	-10%
1 Year:	-36%

Return on Equity
10 Years:	8%
5 Years:	5%
3 Years:	3%
Last Year:	2%

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: December 4, 2025, 2:08 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	29	29	29	30	30	31	31	31	31	31	31	31	31
Reserves	193	218	260	297	341	403	473	527	577	650	670	710	731
Borrowings	0	0	0	0	1	8	6	10	7	7	5	13	7
Other Liabilities	49	51	57	58	75	100	108	115	140	168	168	150	148
Total Liabilities	271	299	347	385	446	541	618	683	755	856	874	903	916
Fixed Assets	92	91	88	89	90	90	100	99	108	107	103	97	96
CWIP	0	0	0	0	0	0	1	1	2	2	0	0	0
Investments	0	0	1	1	1	4	4	5	21	83	17	38	33
Other Assets	179	207	258	295	355	447	513	577	624	665	755	769	788
Total Assets	271	299	347	385	446	541	618	683	755	856	874	903	916

Below is a detailed analysis of the balance sheet data for Trigyn Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
For Reserves, as of Sep 2025, the value is 731.00 Cr.. The value appears strong and on an upward trend. It has increased from 710.00 Cr. (Mar 2025) to 731.00 Cr., marking an increase of 21.00 Cr..
For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 6.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 148.00 Cr.. The value appears to be improving (decreasing). It has decreased from 150.00 Cr. (Mar 2025) to 148.00 Cr., marking a decrease of 2.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 916.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 96.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 96.00 Cr., marking a decrease of 1.00 Cr..
For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
For Investments, as of Sep 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Mar 2025) to 33.00 Cr., marking a decrease of 5.00 Cr..
For Other Assets, as of Sep 2025, the value is 788.00 Cr.. The value appears strong and on an upward trend. It has increased from 769.00 Cr. (Mar 2025) to 788.00 Cr., marking an increase of 19.00 Cr..
For Total Assets, as of Sep 2025, the value is 916.00 Cr.. The value appears strong and on an upward trend. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..

Notably, the Reserves (731.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	-4	0	52	46	15	-18	-1	80	45	-52	126	51
Cash from Investing Activity +	2	5	5	-3	-1	11	12	-9	-21	-22	76	29
Cash from Financing Activity +	-1	-2	-1	-1	-1	7	-5	-5	-6	-3	-4	-3
Net Cash Flow	-3	2	56	43	13	0	6	67	19	-77	198	77

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	44.00	36.00	62.00	67.00	60.00	77.00	71.00	82.00	58.00	54.00	30.00	5.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	105	114	83	68	74	79	104	89	99	87	71	99
Inventory Days						9
Days Payable						407
Cash Conversion Cycle	105	114	83	68	74	-319	104	89	99	87	71	99
Working Capital Days	75	82	57	42	50	62	71	56	57	72	53	64
ROCE %	29%	17%	24%	22%	17%	21%	17%	17%	10%	9%	6%	4%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%	44.51%
FIIs	0.00%	0.22%	0.24%	0.71%	0.17%	0.27%	0.25%	0.15%	0.22%	0.26%	0.14%	0.10%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	55.49%	55.28%	55.24%	54.78%	55.33%	55.22%	55.23%	55.34%	55.27%	55.23%	55.35%	55.38%
No. of Shareholders	37,647	37,235	38,815	36,925	37,298	35,155	33,850	33,832	34,420	34,136	34,157	33,217

Shareholding Pattern Chart

No. of Shareholders

Trigyn Technologies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	3.82	6.48	11.26	12.69	20.20
Diluted EPS (Rs.)	3.82	6.48	11.26	12.69	20.11
Cash EPS (Rs.)	5.45	8.72	13.47	14.87	21.20
Book Value[Excl.RevalReserv]/Share (Rs.)	240.71	227.77	221.21	197.37	181.30
Book Value[Incl.RevalReserv]/Share (Rs.)	240.71	227.77	221.21	197.37	181.30
Revenue From Operations / Share (Rs.)	291.71	415.67	413.41	338.01	320.09
PBDIT / Share (Rs.)	11.51	15.18	21.85	22.18	30.80
PBIT / Share (Rs.)	9.88	12.95	19.64	20.01	29.79
PBT / Share (Rs.)	8.60	12.41	18.92	19.11	28.91
Net Profit / Share (Rs.)	3.82	6.48	11.26	12.69	20.20
NP After MI And SOA / Share (Rs.)	3.82	6.48	11.26	12.69	20.20
PBDIT Margin (%)	3.94	3.65	5.28	6.56	9.62
PBIT Margin (%)	3.38	3.11	4.75	5.91	9.30
PBT Margin (%)	2.94	2.98	4.57	5.65	9.03
Net Profit Margin (%)	1.31	1.56	2.72	3.75	6.30
NP After MI And SOA Margin (%)	1.31	1.56	2.72	3.75	6.30
Return on Networth / Equity (%)	1.58	2.84	5.09	6.43	11.13
Return on Capital Employeed (%)	4.03	5.58	8.73	10.01	16.14
Return On Assets (%)	1.30	2.28	4.05	5.17	9.10
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Total Debt / Equity (X)	0.01	0.00	0.00	0.01	0.01
Asset Turnover Ratio (%)	1.01	1.48	1.58	0.20	0.20
Current Ratio (X)	4.82	4.26	3.36	3.69	4.02
Quick Ratio (X)	4.76	4.21	3.30	3.67	3.99
Inventory Turnover Ratio (X)	109.49	0.00	0.00	0.00	0.00
Interest Coverage Ratio (X)	12.76	28.21	30.01	24.69	34.91
Interest Coverage Ratio (Post Tax) (X)	5.66	13.05	16.47	15.12	23.89
Enterprise Value (Cr.)	-195.88	-48.38	147.35	204.15	3.24
EV / Net Operating Revenue (X)	-0.21	-0.03	0.11	0.19	0.00
EV / EBITDA (X)	-5.53	-1.03	2.19	2.99	0.03
MarketCap / Net Operating Revenue (X)	0.23	0.22	0.22	0.39	0.19
Price / BV (X)	0.28	0.41	0.41	0.68	0.34
Price / Net Operating Revenue (X)	0.23	0.22	0.22	0.39	0.19
EarningsYield	0.05	0.06	0.12	0.09	0.32

After reviewing the key financial ratios for Trigyn Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
For Diluted EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
For Cash EPS (Rs.), as of Mar 25, the value is 5.45. This value is within the healthy range. It has decreased from 8.72 (Mar 24) to 5.45, marking a decrease of 3.27.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 291.71. It has decreased from 415.67 (Mar 24) to 291.71, marking a decrease of 123.96.
For PBDIT / Share (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has decreased from 15.18 (Mar 24) to 11.51, marking a decrease of 3.67.
For PBIT / Share (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has decreased from 12.95 (Mar 24) to 9.88, marking a decrease of 3.07.
For PBT / Share (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 12.41 (Mar 24) to 8.60, marking a decrease of 3.81.
For Net Profit / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
For PBDIT Margin (%), as of Mar 25, the value is 3.94. This value is below the healthy minimum of 10. It has increased from 3.65 (Mar 24) to 3.94, marking an increase of 0.29.
For PBIT Margin (%), as of Mar 25, the value is 3.38. This value is below the healthy minimum of 10. It has increased from 3.11 (Mar 24) to 3.38, marking an increase of 0.27.
For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has decreased from 2.98 (Mar 24) to 2.94, marking a decrease of 0.04.
For Net Profit Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 8. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has decreased from 2.84 (Mar 24) to 1.58, marking a decrease of 1.26.
For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 5.58 (Mar 24) to 4.03, marking a decrease of 1.55.
For Return On Assets (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 5. It has decreased from 2.28 (Mar 24) to 1.30, marking a decrease of 0.98.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.01. It has decreased from 1.48 (Mar 24) to 1.01, marking a decrease of 0.47.
For Current Ratio (X), as of Mar 25, the value is 4.82. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 4.82, marking an increase of 0.56.
For Quick Ratio (X), as of Mar 25, the value is 4.76. This value exceeds the healthy maximum of 2. It has increased from 4.21 (Mar 24) to 4.76, marking an increase of 0.55.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 109.49. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 109.49, marking an increase of 109.49.
For Interest Coverage Ratio (X), as of Mar 25, the value is 12.76. This value is within the healthy range. It has decreased from 28.21 (Mar 24) to 12.76, marking a decrease of 15.45.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has decreased from 13.05 (Mar 24) to 5.66, marking a decrease of 7.39.
For Enterprise Value (Cr.), as of Mar 25, the value is -195.88. It has decreased from -48.38 (Mar 24) to -195.88, marking a decrease of 147.50.
For EV / Net Operating Revenue (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 1. It has decreased from -0.03 (Mar 24) to -0.21, marking a decrease of 0.18.
For EV / EBITDA (X), as of Mar 25, the value is -5.53. This value is below the healthy minimum of 5. It has decreased from -1.03 (Mar 24) to -5.53, marking a decrease of 4.50.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
For Price / BV (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.41 (Mar 24) to 0.28, marking a decrease of 0.13.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Trigyn Technologies Ltd as of March 2, 2026 is: ₹103.31

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 2, 2026, Trigyn Technologies Ltd is Undervalued by 99.06% compared to the current share price ₹51.90

Intrinsic Value of Trigyn Technologies Ltd as of March 2, 2026 is: ₹65.09

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 2, 2026, Trigyn Technologies Ltd is Undervalued by 25.41% compared to the current share price ₹51.90

Last 5 Year EPS CAGR: -36.99%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 16.08%, which is a positive sign. The company has higher reserves (465.38 cr) compared to borrowings (4.92 cr), indicating strong financial stability. The company has shown consistent growth in sales (583.69 cr) and profit (58.85 cr) over the years.	The stock has a high average Working Capital Days of 61.75, which may not be favorable. The stock has a high average Cash Conversion Cycle of 56.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Trigyn Technologies Ltd:
1. Net Profit Margin: 1.31%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 4.03% (Industry Average ROCE: 14.9%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 1.58% (Industry Average ROE: 21%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 5.66
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.76
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 29.8 (Industry average Stock P/E: 101.91)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Trigyn Technologies Ltd. is a Public Limited Listed company incorporated on 25/03/1986 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L72200MH1986PLC039341 and registration number is 039341. Currently Company is involved in the business activities of Computer programming, consultancy and related activities. Company's Total Operating Revenue is Rs. 153.08 Cr. and Equity Capital is Rs. 30.79 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
IT Consulting & Software	Unit 27, SDF 1, Mumbai Maharashtra 400096	Contact not found

Management
Name	Position Held
Dr. Satyam Cherukuri	Chairman & Non-Exe.Director
Ms. P Bhavana Rao	Executive Director
Mr. R Ganapathi	Non Executive Director
Dr. P Raja Mohan Rao	Non Executive Director
Ms. Lakshmi Potluri	Independent Director
Mr. Ishwar Halalli	Independent Director
Mr. Syed Ahmed Sultan	Independent Director
Mr. Vijay Mallya	Independent Director

FAQ

What is the intrinsic value of Trigyn Technologies Ltd?

Trigyn Technologies Ltd's intrinsic value (as of 02 March 2026) is ₹65.09 which is 25.41% higher the current market price of ₹51.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹160 Cr. market cap, FY2025-2026 high/low of ₹102/50.0, reserves of ₹731 Cr, and liabilities of ₹916 Cr.

What is the Market Cap of Trigyn Technologies Ltd?

The Market Cap of Trigyn Technologies Ltd is 160 Cr..

What is the current Stock Price of Trigyn Technologies Ltd as on 02 March 2026?

The current stock price of Trigyn Technologies Ltd as on 02 March 2026 is ₹51.9.

What is the High / Low of Trigyn Technologies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Trigyn Technologies Ltd stocks is ₹102/50.0.

What is the Stock P/E of Trigyn Technologies Ltd?

The Stock P/E of Trigyn Technologies Ltd is 29.8.

What is the Book Value of Trigyn Technologies Ltd?

The Book Value of Trigyn Technologies Ltd is 247.

What is the Dividend Yield of Trigyn Technologies Ltd?

The Dividend Yield of Trigyn Technologies Ltd is 0.00 %.

What is the ROCE of Trigyn Technologies Ltd?

The ROCE of Trigyn Technologies Ltd is 4.17 %.

What is the ROE of Trigyn Technologies Ltd?

The ROE of Trigyn Technologies Ltd is 1.72 %.

What is the Face Value of Trigyn Technologies Ltd?

The Face Value of Trigyn Technologies Ltd is 10.0.